Karen Soares - Oct 31, 2023 Form 3 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Role
General Counsel & Secretary
Signature
/s/Peter J. Rivas as attorney-in-fact for Karen M. Soares
Stock symbol
CLOV
Transactions as of
Oct 31, 2023
Transactions value $
$0
Form type
3
Date filed
11/9/2023, 04:36 PM
Next filing
Nov 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CLOV Class A Common Stock 409K Oct 31, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CLOV Stock Options (right to buy) Oct 31, 2023 Class A Common Stock 20.7K $1.94 Direct F2
holding CLOV Stock Options (right to buy) Oct 31, 2023 Class A Common Stock 20.7K $1.94 Direct F3
holding CLOV Stock Options (right to buy) Oct 31, 2023 Class A Common Stock 42.3K $2.36 Direct F4
holding CLOV Stock Options (right to buy) Oct 31, 2023 Class A Common Stock 40.4K $2.36 Direct F5
holding CLOV Stock Options (right to buy) Oct 31, 2023 Class A Common Stock 31K $3.66 Direct F6
holding CLOV Stock Options (right to buy) Oct 31, 2023 Class A Common Stock 145K $6.64 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported number of securities beneficially owned includes, in part, 317,038 shares of Class A common stock of Clover Health Investments, Corp. (the "Company") underlying the remaining unvested portion, as of October 31, 2023, of time-based restricted stock unit awards originally granted to the Reporting Person on June 15, 2021, February 14, 2022 and September 15, 2022.
F2 Received in connection with a December 12, 2018 grant, covering 20,068 shares of the Company's Class A common stock. 100% of the shares subject to this grant are currently vested and exercisable.
F3 Received in connection with a June 4, 2019 grant, covering 20,680 shares of the Company's Class A common stock. 19,646 of the shares subject to this grant are currently vested and exercisable. The remaining options vest in equal monthly installments, such that the grant will be fully vested on January 1, 2024, subject to the Reporting Person's continued service on each such date.
F4 Received in connection with a April 28, 2020 grant, covering 42,290 shares of the Company's Class A common stock. 100% of the shares subject to this grant are currently vested and exercisable.
F5 Received in connection with a April 28, 2020 grant, covering 40,432 shares of the Company's Class A common stock. 18,372 of the shares subject to this grant are currently vested and exercisable. The remaining options vest in equal monthly installments, such that the grant will be fully vested on February 24, 2025, subject to the Reporting Person's continued service on each such date.
F6 Received in connection with a June 29, 2020 grant, covering 31,021 shares of the Company's Class A common stock. 20,680 of the shares subject to this grant are currently vested and exercisable. The remaining options vest in equal monthly installments, such that the grant will be fully vested on June 1, 2025, subject to the Reporting Person's continued service on each such date.
F7 Received in connection with a September 26, 2020 grant, covering 144,765 shares of the Company's Class A common stock. 91,684 of the shares subject to this grant are currently vested and exercisable. The remaining options vest in equal monthly installments, such that the grant will be fully vested on August 10, 2025, subject to the Reporting Person's continued service on each such date.